

Latvian Institute of Organic Synthesis (IOS) in FP7 and Horizon2020



Dace Kārkle
30.03.2017.

Outline

About IOS

IOS in FP7 & H2020

Major projects

Success factors

Obstacles and suggestions



About IOS



Founded on 1957 to develop new small molecules as medicines and pesticides

An independent public research institute with 270 employees


More than 5000 m² of fully equipped laboratory space

Total income more than 10 MEUR in 2016

Discovered and developed 18 original and more than 70 generic medicines


The leading scientific institution in Latvia, well recognized in European research area by experts from Nordic Council of Ministers (January, 2014)

IOS in FP7 & H2020 I




Source: Ministry of Education and Science, 1.1.1. specifiskā atbalsta mērķa «Palielināt Latvijas zinātnisko institūciju pētniecisko un inovatīvo kapacitāti un spēju piesaistīt ārējo finansējumu, ieguldot cilvēkresursos un infrastruktūrā» 1.1.1.5. pasākuma «Atbalsts starptautiskās sadarbības projektiem pētniecībā un inovācijās» SĀKOTNĒJAIS NOVĒRTEJUMS

IOS in FP7 & H2020 II



	# of submitted and evaluated projects	# of projects above threshold	% of success	# of funded projects	% of success
FP7	32	15	47%	10	31%
H2020	22	20	91%	4	18%
Total	54	35	65%	14	26%

IOS in FP7 projects



**New AntiBacterials with Inhibitory
activity on Aminoacyl-tRNA Synthetases**
EC funding: 0.85 MEUR



**European Gram-Negative
Antibacterial Engine**
EC funding: 6,06 MEUR



**Strengthening the research and innovative
capacities of the Latvian Institute of Organic
Synthesis**
EC funding: 4.7 MEUR

IOS in Horizon 2020

(2014 – 2016)



**Interdisciplinary Training
Network for Validation of Gram-
Negative Antibacterial Targets**
EC funding: EUR 223 578



**Developing new Therapies
for Batten Disease**
EC funding: 399 625 EUR



PELICO
**Peptidomimetics with
Photocontrolled biological
activity**
EC funding: 99 000 EUR



Dr. Kristaps Jaudzems has been awarded **M.Curie Individual fellowship** "Development of high field DNP-enhanced MAS NMR techniques for structure determination of viral capsids" in collaboration with Centre National de la Recherche Scientifique, France

IOS major projects

Project acronym	Name	EC funding
ENABLE https://www.imi.europa.eu/content/enable	European Gram Negative Antibacterial Engine	6 065 000
NABARSI http://www.nabarsi.eu/	New Antibacterials with Inhibitory activity on Aminoacyl-tRNA Synthesis	848 025
InnovaBalt http://www.innovabalt.eu/	Strengthening the research and innovative capacities of the Latvian Institute of Organic Synthesis, the leading Baltic regional centre for drug discovery	4 707 492

IOS major projects (ENABLE)

Aim of the project	To develop attractive antimicrobial candidates for testing in the clinic, bringing the possibility of new antibiotics to treat Gram-negative infections one step closer to patients
Type of project	RTD
Period	2014 - 2020
IOS Role	Partner
Number of Partners	> 30
EC funding	6 065 000
How did we get there	Contacts of the Principal Investigator (PI) established through scientific cooperation

EC audit successfully
completed

IOS major projects (NABARSI)

Aim of the project	To develop a Proof-of-Concept (PoC) for the discovery of new chemical entities (NCEs) as antibacterial drugs, and to exploit the results in conjunction with industry
Type of project	RTD
Period	2013 – 2016
IOS Role	Partner
Number of Partners	5
EC funding	848 025
How did we get there	Contacts of the Principal Investigator (PI) established through contract research project



Licensing agreement signed and next fundraising stage completed

IOS major projects (InnovaBalt)

Aim of the project	To strengthen the multidisciplinary research capacities, management of intellectual property as well as human resources in the innovative drug discovery at LIOS
Type of project	CSA
Period	2013 – 2017
IOS Role	Coordinator
Number of Partners	1
EC funding	4 707 492
How did we get there	The persistence of the project manager (the project proposal was submitted 3 times)



Successive projects of > 2mln. EUR
funded

PARTNER	COORDINATOR
1. Scientific excellence	1. Scientific excellence
2. Personal contacts (backed up by positive cooperation record)	2. Societal and/or industrial interest
3. Being a «convenient» partner	3. Administrative support service and knowledge about structure and functioning of FP7 and H2020

Obstacles and suggestions

OBSTACLES	SUGGESTIONS
No matching topics in the calls	Increased share of bottom – up projects Increased share of Widening Participation projects Participation in Joint Programming Initiatives
«Dying» or uninterested partners	More flexible rules with regard to partner change
Payment delays due to problems with other partners	National liquidity instrument (?)
Lack of harmonization of rules for administrative/financial reporting for FP7 and national Co-funding	Harmonized rules for periodic reports for Framework and Co-funding programmes
Co-financing and VAT	Solved